Raymond James Financial
UTHR icon

Raymond James Financial’s United Therapeutics UTHR Stock Holding History

Raymond James Financial’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.2M Sell
47,576
-901
-2% -$449K 0.01% 1231
2025
Q4 		$23.6M Buy
48,477
+5,509
+13% +$2.57M 0.01% 1325
2025
Q3 		$18M Sell
42,968
-2,890
-6% -$972K 0.01% 1487
2025
Q2 		$13.2M Sell
45,858
-9,687
-17% -$2.9M ﹤0.01% 1666
2025
Q1 		$17.1M Buy
55,545
+3,801
+7% +$1.3M 0.01% 1426
2024
Q4 		$18.3M Buy
+51,744
New +$19M 0.01% 1395

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Raymond James Financial's UTHR Position: Q1 2026 in Review

Raymond James Financial reduced its United Therapeutics (UTHR) stake by 1.9% in Q1 2026, selling an estimated $449K and leaving 47,576 shares worth $28.2M. The position accounts for 0.01% of the portfolio, ranked #1231.

Raymond James Financial first reported a position in UTHR in Q4 2024 and has held it in 6 quarters since. 852 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Raymond James Financial held 47,576 shares of United Therapeutics worth $28.2M as of Q1 2026.
  • Raymond James Financial sold 901 United Therapeutics shares in Q1 2026, an estimated $449K.
  • United Therapeutics made up 0.01% of Raymond James Financial's portfolio in Q1 2026, its #1231 holding.
  • Raymond James Financial first reported a position in United Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 852 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.